Trial Profile
A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tumour cell vaccine-GVAX (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Feb 2023 Status changed from active, no longer recruiting to completed.
- 03 Mar 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
- 03 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.